Imfinzi (durvalumab) 500 mg: Advanced Cancer Immunotherapy
At El-Masry Pharmacy, we provide cutting-edge biological therapies. Imfinzi, containing the monoclonal antibody durvalumab, is a breakthrough treatment developed by AstraZeneca designed to enhance the body's immune response against tumor cells.
Therapeutic Advantages
- Immune Checkpoint Inhibition: By blocking PD-L1, Imfinzi empowers the immune system to recognize and eliminate malignant cells more effectively.
- Standardized Quality: Produced by AstraZeneca to ensure clinical reliability and therapeutic consistency in specialized oncology settings.
- Optimized for Infusion: Designed specifically for intravenous administration post-dilution, allowing for precise clinical dosing.
Technical Product Specifications
Referencing the data in ", the product includes:
- Active Ingredient: Durvalumab.
- Concentration: 500 mg in 10 mL (50 mg/mL).
- Administration: For Intravenous Infusion After Dilution.
- Packaging: Single-dose vial.
Handling and Storage Guidelines
- Store refrigerated at 2°C to 8°C (36°F to 46°F); do not freeze or shake.
- Always store in the original carton to protect from light.
- Discard any unused portion after dilution.
Clinical Disclaimer: Imfinzi is a Prescription Only Medicine (POM) for professional use. Pharmacists are required to dispense the accompanying Medication Guide to each patient. Ensure the vial seal is intact prior to use; do not use if damaged or missing.
You can add a rating once you purchase the product through the My Orders page
